A Randomised, Double-blind, Placebo-controlled Trial to Assess Safety, Tolerability and Pharmacokinetics of Liraglutide in Obese Adolescent Subjects Aged 12 to 17 Years

NCT01789086 · Completed

Last updated 2026-05-28

This clinical trial tested the safety and side effects of the medication liraglutide in adolescents aged 12 to 17 who are obese.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 21 people

Who can join Ages 12–17 · all sexes

Timeline Started 2013-02 · est. completion 2014-05

Where 1 site · Germany

What this study is testing ClinicalTrials.gov NCT01789086 ↗

Description as written by the study sponsor.

This trial is conducted in Europe. The purpose of the trial is to assess safety, tolerability and pharmacokinetics (the exposure of the trial drug in the body) of liraglutide in obese adolescent subjects aged 12 to 17 years.

Treatments tested

liraglutide Drug

Administered subcutaneously (s.c., under skin) for 5-6 weeks. Initial dose of 0.6 mg/day. The dose will be escalated by 0.6 mg/day in weekly steps to a maximum of 3.0 mg/day
placebo Drug

Administered subcutaneously (s.c., under skin) for 5-6 weeks. Initial dose of 0.6 mg/day. The dose will be escalated by 0.6 mg/day in weekly steps to a maximum of 3.0 mg/day

Main thing measured	Number of treatment emergent adverse events (TEAEs)
Sponsor	Novo Nordisk A/S
Conditions studied	Metabolism and Nutrition Disorder, Obesity
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01789086 ↗